TIRBANIBULIN

Details

Stereochemistry	ACHIRAL
Molecular Formula	C26H29N3O3
Molecular Weight	431.5277
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

c1ccc(cc1)CN=C(Cc2ccc(cn2)-c3ccc(cc3)OCCN4CCOCC4)O

InChI

InChIKey=HUNGUWOZPQBXGX-UHFFFAOYSA-N

InChI=1S/C26H29N3O3/c30-26(28-19-21-4-2-1-3-5-21)18-24-9-6-23(20-27-24)22-7-10-25(11-8-22)32-17-14-29-12-15-31-16-13-29/h1-11,20H,12-19H2,(H,28,30)

HIDE SMILES / InChI

Molecular Formula	C26H29N3O3
Molecular Weight	431.5277
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23314737 | https://www.ncbi.nlm.nih.gov/pubmed/27737538

KX-01 is a dual inhibitor of Src kinase and tubulin polymerization. KX01 promotes the induction of p53, G2/M arrest of proliferating cell populations and subsequent apoptosis via the stimulation of Caspase-3 and PARP cleavage. The drug was developed by Kinex Pharmaceuticals and reached phase II of clinical trials for the treatment of Castration-Resistant Prostate Cancer and Actinic Keratosis. KX-01 demonstrated good in vitro pofile against different cancer cell lines with IC50 in nanomolar range.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Tyrosine-protein kinase SRC 16 Target ID: CHEMBL267 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23314737 \| https://www.ncbi.nlm.nih.gov/pubmed/27737538	Inhibitor 7701	Castrate-resistant prostate cancer Actinic keratosis
tubulin complex assembly 1 Target ID: GO:0007021 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23314737 \| https://www.ncbi.nlm.nih.gov/pubmed/27737538	Inhibitor 7701	Castrate-resistant prostate cancer Actinic keratosis

Conditions

Condition	Modality	Targets	Highest Phase	Product
Castrate-resistant prostate cancer 18 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23314737	Primary	Tyrosine-protein kinase SRC tubulin complex assembly	Phase II
Actinic keratosis 9 Sources: https://clinicaltrials.gov/ct2/show/NCT02838628	Primary	tubulin complex assembly Tyrosine-protein kinase SRC	Phase II

PubMed

Title	Date	PubMed
Expression of Src and FAK in hepatocellular carcinoma and the effect of Src inhibitors on hepatocellular carcinoma in vitro.	2009 Jul	18979199
Synthesis and pharmacological evaluation of thieno[2,3-b]pyridine derivatives as novel c-Src inhibitors.	2011 Apr 15	21459579
KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer.	2012 Apr	21509526
A phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket- directed SRC inhibitor, in patients with advanced malignancies.	2013 Aug	23361621

Patents

Sample Use Guides

In Vivo Use Guide

Patients recieve 40 mg of oral KX-01 twice-daily. Ointment form should be applied once daily.

Route of Administration: Other

In Vitro Use Guide

PC3-LN4 human prostate cancer cells were treated with 10(-4)-10(4) nM of KX-01 for 72 hours and GI50 value was determined to be 40 nM.

Substance Class	Chemical Created by `admin` on `Fri Jun 25 21:29:40 UTC 2021` Edited by `admin` on `Fri Jun 25 21:29:40 UTC 2021`
Record UNII	4V9848RS5G
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TIRBANIBULIN

Official Name

English

KX2391

Code

English

KX-2-391

Code

English

KLISYRI

Brand Name

English

2-PYRIDINEACETAMIDE, 5-(4-(2-(4-MORPHOLINYL)ETHOXY)PHENYL)-N-(PHENYLMETHYL)-

Systematic Name

English

N-BENZYL-2-(5-(4-(2-MORPHOLIN-4-YLETHOXY)PHENYL)PYRIDIN-2-YL)ACETAMIDE

Systematic Name

English

KX01

Code

English

TIRBANIBULIN [INN]

Common Name

English

TIRBANIBULIN [WHO-DD]

Common Name

English

KX-01

Code

English

TIRBANIBULIN [USAN]

Common Name

English

KX-2391

Code

English

KX2-391

Code

English

Code System Code Type Description

FDA UNII

4V9848RS5G